Survodutide 6mg

What is Survodutide (6mg)?

Survodutide is a synthetic peptide engineered for research on metabolic regulation and hormone-related signaling pathways. It is classified as a dual-acting peptide analog designed to mimic naturally occurring regulatory peptides involved in metabolic communication. In laboratory investigations, Survodutide has been studied for its effects on energy balance, glucose metabolism, and endocrine signaling pathways. Structurally, Survodutide is composed of a modified amino acid chain designed to improve stability and resistance to enzymatic degradation in experimental settings. It is used in research to explore metabolic signaling mechanisms and the biological effects of peptide-based hormone analogs.

What are the key features of Survodutide (6mg)?

• Purity: ≥98%, verified through HPLC analysis
• Subcategory: Weight Loss & Metabolic Peptides
• CAS Number: 2805997-46-8
• Molecular Weight: 4231.63 g/mol
• Chemical Formula: C₁₉₂H₂₈₉N₄₇O₆₁
• Peptide Sequence: His-{1-Aminocyclobutanecarboxylic acid}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Arg-Ala-Ala-Lys-Asp-Phe-Ile-{Lys(Gly-Ser-Gly-Ser-Gly-Gly-γGlu-C18 diacid)}-Trp-Leu-Glu-Ser-Ala-NH2
• Format: Lyophilized powder in a sterile 6 mg research vial
• Identity Confirmation: Mass spectrometry (MS) and chromatographic methods
• Research Focus: Metabolic and endocrine signaling pathways
• For Laboratory Research Use Only

How is Survodutide (6mg) synthesized?

Survodutide is produced via solid-phase peptide synthesis (SPPS), a widely-used method for manufacturing research peptides. This process involves the sequential assembly of specific amino acids into a peptide chain. Controlled synthesis conditions enable researchers to generate precise peptide sequences that resemble naturally occurring metabolic signaling peptides while incorporating structural modifications to enhance stability in laboratory experiments. After synthesis, the peptide undergoes purification using high-performance liquid chromatography (HPLC) to remove incomplete sequences and impurities. Mass spectrometry (MS) is then used for analytical verification, confirming the molecular weight and sequence accuracy. These verification methods ensure that the final peptide meets research-grade standards.

What is Survodutide (6mg) being studied for? What are its possible benefits?

Survodutide has been investigated in experimental models focused on metabolic regulation and energy balance. Because the peptide is designed to mimic biological signaling molecules, researchers use it as a tool to examine how hormone-like peptides influence metabolic pathways. Research areas involving Survodutide include:

• Metabolic signaling and energy regulation
• Interactions between peptide hormones and glucose metabolism
• Laboratory studies of lipid metabolism and adipose tissue signaling
• Investigations of endocrine pathway communication
• Exploring how peptides with similar structures influence cellular energy utilization and metabolic feedback loops

These biological effects are still under investigation in laboratory settings. Current findings should not be interpreted as established therapeutic outcomes.

How does Survodutide (6mg) work in research studies?

In laboratory settings, Survodutide is studied for its potential to modulate metabolic signaling networks. Researchers examine how the compound interacts with biological systems that regulate energy balance, nutrient sensing, and hormone-driven metabolic responses. In simplified terms, Survodutide may affect cellular signaling pathways that coordinate metabolic activity across multiple tissues. These pathways are involved in processes such as nutrient processing, cellular energy management, and endocrine communication between organs. Scientists use this peptide in experimental models to observe how synthetic hormone analogs influence protein signaling cascades and metabolic feedback mechanisms. These studies help researchers understand how peptide-based regulators may shape metabolic responses in controlled research environments.

What dosing information exists for Survodutide (6mg)?

Published data on Survodutide dosing primarily come from experimental and preclinical studies. In many laboratory models, peptide compounds such as Survodutide are studied at doses adjusted for body weight. For example, some metabolic studies have explored doses ranging from 10–100 µg/kg in animal models to evaluate biological signaling responses. In in vitro experiments, researchers may examine cellular activity at concentrations in the nanomolar to micromolar range. These concentrations allow researchers to observe peptide-driven signaling changes in cultured cells under controlled conditions. It is important to note that these dosing parameters are used in research models and do not represent standardized guidelines for human or veterinary use.

How should Survodutide (6mg) be stored and handled?

Proper storage is essential to maintain peptide stability during laboratory use. Survodutide, supplied as a lyophilized powder, should be stored at –20 °C or lower in sealed containers protected from light and moisture. Once reconstituted with an appropriate laboratory solvent, peptide solutions are generally stored at 2–8 °C for short-term use. Reconstituted solutions should be handled using sterile laboratory techniques to prevent contamination. Repeated freeze-thaw cycles should be avoided as they may affect peptide stability. Proper handling and storage ensure the integrity of the peptide during experimental procedures.

Where can I read more research about Survodutide (6mg)?

1. Zimmermann T, Thomas L, Baader-Pagler T, et al. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Mol Metab. 2022;66:101633. doi:10.1016/j.molmet.2022.101633
2. National Center for Biotechnology Information. PubChem Compound Summary for CID 168429725, Survodutide. https://pubchem.ncbi.nlm.nih.gov/compound/Survodutide
3. Thomas L, Martel E, Rist W, et al. The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection. Diabetes Obes Metab. 2024;26(6):2368-2378. doi:10.1111/dom.15551
4. Li Y, Zhou Q, Dai A, et al. Structural analysis of the dual agonism at GLP-1R and GCGR. Proceedings of the National Academy of Sciences. 2023;120(33):e2303696120. doi:10.1073/pnas.2303696120

Compliance Statement

This product is intended for laboratory research use only and is not approved for human or veterinary use.